Cerezyme is the only Type 1 Gaucher disease treatment backed by Genzyme's extensive educational, clinical and patient support resources.

Genzyme is committed to helping meet the needs of people who are living with Gaucher disease. As part of this commitment, we provide services for those who have Type 1 Gaucher disease, their families, and caregivers. In addition, we offer links to other organizations that provide information and support to the Gaucher community.

Getting reliable information, finding support for yourself, and identifying treatment centers with expertise in Type 1 Gaucher disease are all critical in managing the disorder. In this section, you will find sources for all these avenues of support. Our goal is to help patients and families advocate for themselves and receive the highest quality care.

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies). These patients have a higher risk of an allergic reaction (hypersensitivity). Use Cerezyme® (imiglucerase for injection) carefully if you have had an allergic reaction to the product in the past. Symptoms suggestive of allergic reaction happened in 6.6% of patients, and include anaphylactoid reaction (a serious allergic reaction), itching, flushing, hives, an accumulation of fluid under the skin, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure.

Side effects related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported side effects include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Because Cerezyme therapy is administered by intravenous infusion, reactions at the site of injection may occur: discomfort, itching, burning, swelling or uninfected abscess. Cerezyme is available by prescription only. For more information, consult your physician.

Please see Full Prescribing Information (PDF).

Cerezyme is the only therapy with over 17 years of use in over 5,600 Gaucher patients, including children.